rss

Register now to receive the Table of Contents and other relevant alerts by email each issue

November 2007, Volume 66, suppl 3

Advances in targeted therapies IX

[Author index]

Cover
  1. Preface
  2. Consensus statement
  3. Opening lectures
  4. Looking at clinical trials and more
  5. Animal models
  6. Novel targets I
  7. Insights from investigator-driven trials and genetics
  8. The lupus connection
  9. Novel targets II
  10. Novel targets III
[Search ALL Issues]

View multiple abstracts by picking relevant boxes and click Get all checked abstracts

Issue information

[Table of contents PDF][Front matter PDF]
Special Data Supplement for this Issue:

Preface

  • Advances in targeted therapies IX

    Ann Rheum Dis 2007;66:(Supplement suppl_3) iii1 doi:10.1136/ard.2007.079772

Consensus statement

  • Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007

    • D E Furst,
    • F C Breedveld,
    • J R Kalden,
    • J S Smolen,
    • G R Burmester,
    • J Sieper,
    • P Emery,
    • E C Keystone,
    • M H Schiff,
    • P Mease,
    • P L C M van Riel,
    • R Fleischmann,
    • M H Weisman,
    • M E Weinblatt
    Ann Rheum Dis 2007;66:(Supplement suppl_3) iii2-iii22 doi:10.1136/ard.2007.081430

Opening lectures

  • Actin cytoskeleton dynamics linked to synovial fibroblast activation as a novel pathogenic principle in TNF-driven arthritis

    • Y Vasilopoulos,
    • V Gkretsi,
    • M Armaka,
    • V Aidinis,
    • G Kollias
    Ann Rheum Dis 2007;66:(Supplement suppl_3) iii23-iii28 doi:10.1136/ard.2007.079822

  • New therapies for sepsis: focus on the interleukin (IL)12 family member IL27

    Ann Rheum Dis 2007;66:(Supplement suppl_3) iii29-iii31 doi:10.1136/ard.2007.078337

  • Interpreting measurements of physical function in clinical trials

    Ann Rheum Dis 2007;66:(Supplement suppl_3) iii32-iii34 doi:10.1136/ard.2007.079806

  • Thoughts on health economics in rheumatoid arthritis

    Ann Rheum Dis 2007;66:(Supplement suppl_3) iii35-iii39 doi:10.1136/ard.2007.078964

Looking at clinical trials and more

  • Minimal clinically important improvement/difference (MCII/MCID) and patient acceptable symptom state (PASS): what do these concepts mean?

    • Tore K Kvien,
    • Turid Heiberg,
    • Kåre B Hagen
    Ann Rheum Dis 2007;66:(Supplement suppl_3) iii40-iii41 doi:10.1136/ard.2007.079798

  • Joint remodelling in inflammatory disease

    Ann Rheum Dis 2007;66:(Supplement suppl_3) iii42-iii44 doi:10.1136/ard.2007.078972

Animal models

  • Amplifying elements of arthritis and joint destruction

    • Wim B van den Berg,
    • Peter L van Lent,
    • Leo A B Joosten,
    • Shahla Abdollahi-Roodsaz,
    • Marije I Koenders
    Ann Rheum Dis 2007;66:(Supplement suppl_3) iii45-iii48 doi:10.1136/ard.2007.079830

Novel targets I

  • Schnurri-3 is an essential regulator of osteoblast function and adult bone mass

    • Dallas C Jones,
    • Marc N Wein,
    • Laurie H Glimcher
    Ann Rheum Dis 2007;66:(Supplement suppl_3) iii49-iii51 doi:10.1136/ard.2007.078352

  • α-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs

    • Thomas A Luger,
    • Thomas Brzoska
    Ann Rheum Dis 2007;66:(Supplement suppl_3) iii52-iii55 doi:10.1136/ard.2007.079780

Insights from investigator-driven trials and genetics

  • Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility

    • M F Bakker,
    • J W G Jacobs,
    • S M M Verstappen,
    • J W J Bijlsma
    Ann Rheum Dis 2007;66:(Supplement suppl_3) iii56-iii60 doi:10.1136/ard.2007.078360

The lupus connection

  • Disease activity assessment in SLE: do we have the right instruments?

    Ann Rheum Dis 2007;66:(Supplement suppl_3) iii61-iii64 doi:10.1136/ard.2007.078477

  • Systemic lupus erythematosus: new molecular targets

    • José C Crispín,
    • Vasileios Kyttaris,
    • Yuang-Taung Juang,
    • George C Tsokos
    Ann Rheum Dis 2007;66:(Supplement suppl_3) iii65-iii69 doi:10.1136/ard.2007.078493

Novel targets II

  • Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy

    • Elena Gonzalez-Rey,
    • Per Anderson,
    • Mario Delgado
    Ann Rheum Dis 2007;66:(Supplement suppl_3) iii70-iii76 doi:10.1136/ard.2007.078519

  • Update on toll-like receptor-directed therapies for human disease

    • Kevin Tse,
    • Anthony A Horner
    Ann Rheum Dis 2007;66:(Supplement suppl_3) iii77-iii80 doi:10.1136/ard.2007.078998

  • Could toll-like receptors provide a missing link in chronic inflammation in rheumatoid arthritis? Lessons from a study on human rheumatoid tissue

    • Sandra M Sacre,
    • Stefan K Drexler,
    • Evangelos Andreakos,
    • Marc Feldmann,
    • Fionula M Brennan,
    • Brian M J Foxwell
    Ann Rheum Dis 2007;66:(Supplement suppl_3) iii81-iii86 doi:10.1136/ard.2007.079012

Novel targets III

  • Interplay between pathogenic Th17 and regulatory T cells

    Ann Rheum Dis 2007;66:(Supplement suppl_3) iii87-iii90 doi:10.1136/ard.2007.078527

  • Regulatory T cells and toll-like receptors: regulating the regulators

    • Roger Sutmuller,
    • Anja Garritsen,
    • Gosse J Adema
    Ann Rheum Dis 2007;66:(Supplement suppl_3) iii91-iii95 doi:10.1136/ard.2007.078535

View multiple abstracts by picking relevant boxes and click Get all checked abstracts

Register for free content


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of ARD.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

    • Latest Rheumatology Jobs

    Rheumatology Jobs

    Show me all
    Rheumatology jobs >>